← Back to Screener
Black Diamond Therapeutics, Inc. Common Stock (BDTX)
Price$3.05
Favorite Metrics
Price vs S&P 500 (26W)-33.93%
Price vs S&P 500 (4W)35.53%
Market Capitalization$175.30M
P/E Ratio (Annual)7.84x
All Metrics
P/CF (Annual)5.92x
Book Value / Share (Quarterly)$1.96
P/TBV (Annual)1.01x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$0.52
Price vs S&P 500 (YTD)21.79%
EPS (TTM)$0.38
10-Day Avg Trading Volume0.85M
EPS Excl Extra (TTM)$0.38
EPS (Annual)$0.39
ROI (Annual)19.93%
Cash / Share (Quarterly)$2.25
P/E Basic Excl Extra (TTM)7.84x
P/E Normalized (Annual)7.84x
ROA (Last FY)15.64%
EBITD / Share (TTM)$0.33
ROE (5Y Avg)-55.45%
Cash Flow / Share (Annual)$0.52
P/B Ratio1.56x
P/B Ratio (Quarterly)1.23x
Net Income / Employee (Annual)$1
Net Interest Coverage (TTM)-413.41x
ROA (TTM)13.91%
EV / EBITDA (TTM)8.28x
EPS Incl Extra (Annual)$0.39
Current Ratio (Annual)8.42x
Quick Ratio (Quarterly)8.18x
3-Month Avg Trading Volume0.79M
52-Week Price Return125.00%
EV / Free Cash Flow (Annual)5.21x
P/E Incl Extra (TTM)7.84x
Revenue / Employee (TTM)$3
Tangible BV / Share (Quarterly)$2.60
P/S Ratio (Annual)2.50x
Asset Turnover (Annual)0.49x
52-Week High$4.94
EPS Excl Extra (Annual)$0.39
Tangible BV CAGR (5Y)82.07%
26-Week Price Return-25.18%
Quick Ratio (Annual)8.18x
13-Week Price Return9.68%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.42x
Enterprise Value$154.314
Book Value / Share Growth (5Y)-25.45%
Revenue / Employee (Annual)$3
Pretax Margin (Annual)31.95%
Cash / Share (Annual)$2.25
3-Month Return Std Dev68.32%
Net Income / Employee (TTM)$1
ROE (Last FY)19.93%
Net Interest Coverage (Annual)-12.43x
EPS Basic Excl Extra (Annual)$0.39
EV / Free Cash Flow (TTM)5.21x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$0.38
ROI (TTM)17.46%
Revenue / Share (Annual)$1.22
Tangible BV / Share (Annual)$3.18
Forward P/E4.75x
Price vs S&P 500 (52W)89.91%
P/E Ratio (TTM)7.84x
Year-to-Date Return25.93%
5-Day Price Return12.50%
EPS Normalized (Annual)$0.39
ROA (5Y Avg)-40.44%
Net Profit Margin (Annual)31.95%
Month-to-Date Return43.66%
Cash Flow / Share (TTM)$-2.09
EBITD / Share (Annual)$0.32
Operating Margin (Annual)17.89%
P/CF (TTM)5.92x
ROI (5Y Avg)-55.45%
P/E Excl Extra (TTM)7.84x
EPS Basic Excl Extra (TTM)$0.38
P/TBV (Quarterly)0.87x
P/B Ratio (Annual)1.23x
Book Value / Share (Annual)$1.96
Price vs S&P 500 (13W)6.81%
Beta3.44x
P/FCF (Annual)5.92x
Revenue / Share (TTM)$1.23
ROE (TTM)17.46%
52-Week Low$1.31
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.20
4.20
4.20
4.20
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BDTXBlack Diamond Therapeutics, Inc. Common Stock | — | — | — | — | $3.05 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Black Diamond Therapeutics is a clinical-stage oncology company developing small molecule therapies targeting specific cancer mutations across multiple tumor types. The company's proprietary Mutation-Allostery-Pharmacology platform identifies drug targets in families of oncogenic mutations, addressing a significant market opportunity in precision cancer medicine. Its pipeline includes two lead programs, BDTX-4933 and BDTX-1535.